Startseite>>Signaling Pathways>> Cell Cycle/Checkpoint>> PLK>>Mps1-IN-2

Mps1-IN-2

Katalog-Nr.GC15745

Mps1-IN-2 ist ein potenter, selektiver und ATP-kompetitiver dualer Mps1/Plk1-Inhibitor mit einem IC50 und einer Kd von 145 nM und 12 nM fÜr Mps1 und einer Kd von 61 nM fÜr Plk1.

Products are for research use only. Not for human use. We do not sell to patients.

Mps1-IN-2 Chemische Struktur

Cas No.: 1228817-38-6

Größe Preis Lagerbestand Menge
10mg
141,00 $
Auf Lager
25mg
208,00 $
Auf Lager
50mg
298,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Mps1-IN-2 is a potent and selective ATP-competitive inhibitor of Mps1 kinase with the IC50 value of 145nM [1].

Mps1-IN-2 has been reported to inhibit Mps1 kinase activity with the IC50 value of 145nM, when screened at 1μM ATP. In addition, Mps1-IN-2 has shown greater than 1000-fold selectivity to the Alk and Ltk enzyme. Moreover, Mps1-IN-2 has been revealed to bound to the ATP biding pocket of Mpa1 and formed a hydrogen bond with the hinge backbone (Glu603) at 2.74-Å resolution. Mps1-IN-2 has been noted to abrogate SAC function and override the checkpoint through direct inhibition of Mps1[1].

References:
[1] Kwiatkowski N1, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, Pellman D, Shah JV, Kops GJ, Knapp S, Gray NS. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol. 2010 May;6(5):359-68. doi: 10.1038/nchembio.345. Epub 2010 Apr 11.

Bewertungen

Review for Mps1-IN-2

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Mps1-IN-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.